CA3009799A1 - Particles encapsulating fusion proteins containing linked epitopes - Google Patents

Particles encapsulating fusion proteins containing linked epitopes Download PDF

Info

Publication number
CA3009799A1
CA3009799A1 CA3009799A CA3009799A CA3009799A1 CA 3009799 A1 CA3009799 A1 CA 3009799A1 CA 3009799 A CA3009799 A CA 3009799A CA 3009799 A CA3009799 A CA 3009799A CA 3009799 A1 CA3009799 A1 CA 3009799A1
Authority
CA
Canada
Prior art keywords
seq
nos
biodegradable particle
disease
antigenic epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3009799A
Other languages
English (en)
French (fr)
Inventor
Daniel R. Getts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cour Pharmaceuticals Development Co Inc
Original Assignee
Cour Pharmaceuticals Development Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cour Pharmaceuticals Development Co Inc filed Critical Cour Pharmaceuticals Development Co Inc
Publication of CA3009799A1 publication Critical patent/CA3009799A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3009799A 2016-01-04 2017-01-04 Particles encapsulating fusion proteins containing linked epitopes Pending CA3009799A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662274711P 2016-01-04 2016-01-04
US62/274,711 2016-01-04
PCT/US2017/012173 WO2017120222A1 (en) 2016-01-04 2017-01-04 Particles encapsulating fusion proteins containing linked epitopes

Publications (1)

Publication Number Publication Date
CA3009799A1 true CA3009799A1 (en) 2017-07-13

Family

ID=59274014

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3009799A Pending CA3009799A1 (en) 2016-01-04 2017-01-04 Particles encapsulating fusion proteins containing linked epitopes

Country Status (6)

Country Link
US (2) US20190365656A1 (enExample)
EP (1) EP3400069A4 (enExample)
JP (3) JP6904959B2 (enExample)
CA (1) CA3009799A1 (enExample)
IL (2) IL260296B2 (enExample)
WO (1) WO2017120222A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025027015A1 (en) * 2023-08-01 2025-02-06 Diamante Srl Composition and methods for treating multiple sclerosis

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
EP3760223A1 (en) 2013-04-03 2021-01-06 N-Fold Llc Nanoparticle composition for desensitizing a subject to peanut allergens
EP3247384B1 (en) * 2015-01-14 2023-10-04 The Regents of the University of Colorado, a body corporate In vitro method of diagnosis of type 1 diabetes with insulin mimotopes
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CN109475628A (zh) 2016-05-18 2019-03-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
AU2017379900B2 (en) 2016-12-22 2024-12-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118B1 (en) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
KR102661060B1 (ko) * 2017-07-06 2024-04-25 니토 보세키 가부시기가이샤 항인간 IgG4 모노클로날 항체, 및 그 항체를 이용한 인간 IgG4 측정 시약
JP2021500855A (ja) * 2017-09-07 2021-01-14 キュー バイオファーマ， インコーポレイテッド 抗原提示ポリペプチドおよびその使用方法
WO2019131769A1 (ja) * 2017-12-26 2019-07-04 公立大学法人名古屋市立大学 新規抗ｐａｄ４抗体
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN110041408B (zh) * 2018-01-16 2021-05-18 华中科技大学 一种小分子多肽及其在制备防治帕金森综合症药物中的应用
MX2020013155A (es) 2018-06-05 2021-04-29 Anji Pharma Us Llc Composiciones y metodos para tratar la pancreatitis.
MA52870A (fr) * 2018-06-13 2021-04-21 Acraf Peptides ayant une activité inhibitrice sur le récepteur muscarinique m3
AU2020316005A1 (en) * 2019-07-19 2022-02-24 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disorders
US20230302083A1 (en) * 2020-04-20 2023-09-28 The General Hospital Corporation Highly-networked coronavirus immunogen composition
EP4149534A4 (en) 2020-05-12 2024-09-04 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
IT202000010888A1 (it) * 2020-05-13 2021-11-13 Consiglio Nazionale Ricerche Nanovescicole di mielina e loro impieghi
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
GB202017119D0 (en) * 2020-10-28 2020-12-09 Oxford Vacmedix Uk Ltd Polypeptides for cancer treatment
JP2024518277A (ja) 2021-04-16 2024-05-01 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 免疫寛容の維持を追跡する方法
CN117957017A (zh) * 2021-05-11 2024-04-30 牛津疫苗医学公司 包含重组重叠肽和天然蛋白质的疫苗制剂
US20250084126A1 (en) * 2021-07-07 2025-03-13 Osaka University Peptide and composition
MX2024004851A (es) 2021-10-21 2024-06-12 Cour Pharmaceuticals Dev Company Inc Tratamiento de cirrosis biliar primaria (pbc) con nanoparticulas tolerizantes.
EP4436557A4 (en) * 2021-11-24 2025-06-11 Cour Pharmaceuticals Development Company Inc. PRODUCTION OF TOLERANT NANOPARTICLES FOR THE TREATMENT OF PEANUT ALLERGY
WO2023180547A1 (en) * 2022-03-24 2023-09-28 Julius-Maximilians-Universität Würzburg Mhc ib-mediated islet-antigen-specific immunosuppression as a novel treatment for type 1 diabetes
CN119173251A (zh) 2022-04-29 2024-12-20 库尔制药开发公司 用于克服治疗性载体和蛋白质的免疫原性的耐受性免疫修饰纳米粒子
CN115541872A (zh) * 2022-09-22 2022-12-30 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种pd-l1检测试剂盒及其检测方法
CN120282796A (zh) 2022-10-19 2025-07-08 库尔制药开发公司 用耐受性纳米颗粒治疗花生过敏
CN115771883B (zh) * 2022-11-28 2024-02-23 淮阴工学院 从酿酒酵母发酵液中提取的蛋白酶a在化学法合成纳米硒形貌控制和稳定性影响中的用途
KR20250162851A (ko) 2023-03-24 2025-11-19 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. 중증 근무력증 치료를 위한 관용화 면역 변형 나노입자
WO2024243410A1 (en) 2023-05-23 2024-11-28 Cour Pharmaceuticals Development Company Inc. Preparation of tolerizing nanoparticles for the treatment of primary biliary cholangitis
TW202500576A (zh) 2023-05-25 2025-01-01 美商庫爾製藥發展公司股份有限公司 以免疫耐受性(tolerizing)奈米粒子治療1型糖尿病(t1d)
WO2025043196A2 (en) * 2023-08-24 2025-02-27 The Trustees Of Indiana University Anti-cancer peptides, and methods and uses thereof
WO2025199149A1 (en) 2024-03-18 2025-09-25 Cour Pharmaceuticals Development Company Inc. Sting agonism for antigen specific tolerance

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2352738A1 (en) * 1998-12-04 2000-06-08 Biogen, Inc. Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
WO2001094944A2 (en) * 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
EP2185195A2 (en) * 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
JP6200806B2 (ja) * 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
BR112013004288A2 (pt) * 2010-08-23 2016-05-31 Selecta Biosciences Inc formas galênicas de múltiplos epítopos direcionados para indução de uma resposta imunológica a antigênios.
AU2013221187B9 (en) * 2012-02-16 2018-01-04 Vlp Therapeutics, Inc. Virus like particle composition
KR20250052503A (ko) * 2012-06-21 2025-04-18 노쓰웨스턴유니버시티 펩티드 접합된 입자
JP6553033B2 (ja) * 2013-08-13 2019-07-31 ノースウェスタン ユニバーシティ ペプチドコンジュゲート粒子
JP2019504895A (ja) * 2016-02-09 2019-02-21 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025027015A1 (en) * 2023-08-01 2025-02-06 Diamante Srl Composition and methods for treating multiple sclerosis

Also Published As

Publication number Publication date
JP7730867B2 (ja) 2025-08-28
EP3400069A1 (en) 2018-11-14
IL260296B1 (en) 2023-09-01
IL260296A (en) 2018-08-30
US20240122864A1 (en) 2024-04-18
JP2019507113A (ja) 2019-03-14
EP3400069A4 (en) 2019-09-25
JP6904959B2 (ja) 2021-07-21
IL260296B2 (en) 2024-01-01
JP2021143206A (ja) 2021-09-24
WO2017120222A1 (en) 2017-07-13
JP2023160828A (ja) 2023-11-02
JP7333360B2 (ja) 2023-08-24
US20190365656A1 (en) 2019-12-05
IL304580A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
US20240122864A1 (en) Particles encapsulating fusion proteins containing linked epitopes
AU2020244453B2 (en) Peptide conjugated particles
US11160851B2 (en) Peptide conjugated particles
JP2025181835A (ja) 結合エピトープを含有する融合タンパク質を封入する粒子
WO2019246408A2 (en) Antibody linked peptide based immunotherapy for type 1 diabetes

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211215

EEER Examination request

Effective date: 20211215

EEER Examination request

Effective date: 20211215

EEER Examination request

Effective date: 20211215

EEER Examination request

Effective date: 20211215

EEER Examination request

Effective date: 20211215

EEER Examination request

Effective date: 20211215